PureTech Health (GB:PRTC) has released an update.
PureTech Health’s Seaport Therapeutics has successfully closed a $225 million Series B financing round, led by General Atlantic, to advance its innovative neuropsychiatric medicines using the Glyph technology platform. This financing round boosts Seaport’s total capital raised to $325 million, enabling the company to pursue clinical milestones and develop first-in-class treatments for conditions like major depressive disorder and generalized anxiety disorder. Investors see promise in the Glyph platform’s ability to enhance drug bioavailability and reduce side effects, paving the way for transformative therapies.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
